|

A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms

RECRUITINGPhase 1Sponsored by Damora Therapeutics
Actively Recruiting
PhasePhase 1
SponsorDamora Therapeutics
Started2026-09
Est. completion2030-06
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations25 sites

Summary

This is a multi-center, open-label, Phase 1/1b study designed to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of DMR-001 monotherapy in adult participants with CALR-mutated essential thrombocythemia (ET) and myelofibrosis (MF), and of DMR-001 in combination with ruxolitinib in participants with CALR-mutant MF.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and the protocol.
* Diagnosis/confirmation of ET or MF as defined in the protocol.
* Documented CALR exon-9 mutation.
* Willingness to undergo bone marrow biopsy and aspiration per the Schedule of Assessments.

Exclusion Criteria:

* Presence of any malignancy unless participant has been disease free for at least 2 years.
* History of major bleeding or thrombosis within the last 3 months prior to study enrollment.
* Prior hematopoietic stem cell transplantation or donor leukocyte infusion, or such transplantation or infusion is planned.
* Participants with laboratory values exceeding protocol defined thresholds.
* History of clinically significant or uncontrolled cardiac disease.
* Active HBV, HCV or HIV.
* Known hypersensitivity to DMR-001 or ruxolitinib or any of their components.

Other protocol defined Inclusion/Exclusion Criteria may apply.

Conditions2

CancerMyeloproliferative Neoplasms (MPNs)

Interventions2

Locations25 sites

Site US07
Birmingham, Alabama, 35233
Site US26
Gilbert, Arizona, 85234
Site US11
Duarte, California, 91010
Site US25
Irvine, California, 92618
Site US04
Tampa, Florida, 33612

Find trials near these locations

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.